key: cord-0745904-dtj1i32w
authors: Kaushik, Shubhi; Aydin, Scott I.; Derespina, Kim R.; Bansal, Prerna B.; Kowalsky, Shanna; Trachtman, Rebecca; Gillen, Jennifer K.; Perez, Michelle M.; Soshnick, Sara H.; Conway, Edward E.; Bercow, Asher; Seiden, Howard S.; Pass, Robert H.; Ushay, Henry M.; Ofori-Amanfo, George; Medar, Shivanand S.
title: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City
date: 2020-06-14
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.06.045
sha: 9facaeb5f4b65922eae63cc39e02dd974d5108dc
doc_id: 745904
cord_uid: dtj1i32w

OBJECTIVE: To assess clinical characteristics and outcomes of SARS-CoV-2 associated multisystem inflammatory syndrome in children (MIS-C). STUDY DESIGN: Children with MIS-C admitted to pediatric intensive care units (PICU) in New York City between April 23 and May 23, 2020 were included. Demographic and clinical data were collected. RESULTS: Of 33 children with MIS-C, the median age was 10 years; 61% were male; 45% were Hispanic/Latino; 39% were black. Comorbidities were present in 45%. Fever (93%) and vomiting (69%) were the most common presenting symptoms. Depressed left ventricular ejection fraction (LVEF) was found in 63% of patients with median EF of 46.6% (IQR 39.5, 52.8). C-reactive protein, procalcitonin, D-dimer, and pro-B-type natriuretic peptide levels were elevated in all patients. For treatment, intravenous immunoglobulin was used in 18 (54%), corticosteroids in 17 (51%), tocilizumab in 12 (36%), remdesivir in 7 (21%), vasopressors in 17 (51%), mechanical ventilation in 5 (15%), extracorporeal membrane oxygenation (ECMO) in 1 (3%), and intra-aortic balloon pump in 1 (3%). The LVEF normalized in 95% of those with depressed EF. All patients were discharged home with median duration of PICU stay of 4.7 (4, 8) days and hospital stay of 7.8 (6, 10.1) days. One (3%) patient died after withdrawal of care secondary to stroke while on ECMO. CONCLUSIONS: Critically ill children with COVID-19 associated MIS-C have a spectrum of severity broader than described previously but still require careful supportive intensive care. Rapid, complete clinical and myocardial recovery was almost universal.

The initial reports from China of SARS-CoV-2 in children have infrequently described critically ill children. (1) However, reports from the United States demonstrate a higher rate of critical illness in children with COVID. (2, 3) Reports have begun to emerge of multisystem involvement with circulatory shock and systemic inflammation that has presented predominantly in children with COVID-19. The first report of this syndrome was from the United Kingdom comprising a cohort of 8 children with evidence of severe inflammation and Kawasaki disease-like features.

(4) These reports continued, with subsequent reports from Italy describing 10 children (5) The detailed clinical profile, therapies, interventions, and outcomes in children from the United States with MIS-C are lacking. We report a multicenter cohort of children with COVID-19 associated MIS-C from the epicenter of COVID-19 in New York City, describing the spectrum of clinical presentation, hospital course, therapies, and outcomes.

This is a retrospective observational study of pediatric patients (aged one month to 21 years) with a confirmed infection with SARS-CoV-2 who meet criteria for MIS-C admitted from April 23to May 23, 2020 to three New York City tertiary care children's hospitals [Children's Hospital 6 at Montefiore (CHAM), Mount Sinai Kravis Children's Hospital (KCH), and Jacobi Medical Center (JMC)]; the Institutional Review Boards at the three institutions have approved this multicenter study. Waiver of informed consent was obtained with only de-identified data transmitted and analyzed. Four patients of the 16 reported from KCH were previously described in a recently published case series (9) . Additionally, some of the patients' data are being reported to an ongoing Society of Critical Care Medicine's national registry: Discovery Virus Infection and Respiratory Illness Universal Study (VIRUS) COVID-19 Registry.

A confirmed case of COVID-19 was defined as a positive result from real-time reverse transcription polymerase chain reaction (RT-PCR) testing of a specimen using a nasopharyngeal swab for SARS-CoV-2 or positive SARS-CoV-2 antibody assay. The CDC case definition for MIS-C (8) is used to define a confirmed case of MIS-C, which is as follows: An individual aged <21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); and No alternative plausible diagnoses; and Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms.

There were additional suspected patients with similar symptomatology and management without confirmed SARS-CoV-2 infection/exposure, which were not included as we strictly intended to include only cases confirmed by positive SARS-CoV-2 RT-PCR or antibody assay.

Depressed left ventricular (LV) function was defined as an LV ejection fraction (LVEF) of <50%, and severely depressed LV function as an LVEF <30%.

Demographic, clinical, and outcome data were recorded. Race/ethnicity was identified by documentation in the medical record or by surname for some Latino patients when not documented. Laboratory and radiologic results were recorded as well. All tests and treatments were performed at the discretion of the treating physicians.

Statistics for the study were descriptive with data presented as numbers with percentages and continuous data as median with interquartile range (IQR).

Thirty-three children met criteria for confirmed MIS-C among the three centers and were included in the final cohort and analyses; demographics and baseline clinical characteristics are presented in Table I . Median age was 10 (IQR 6, 13) years; 61% of patients were male. Fifteen (45%) patients were Hispanic/Latino; 13 (39%) patients were black. Median weight was 33.4 (IQR 20.7, 60) kg with median BMI 18.6 (IQR 15.9, 22.9) kg/m 2 . Four (12%) patients were overweight, and 2 (6%) patients were obese. Comorbid conditions were present in 16 (48%) patients. Common presenting symptoms include fever (93%), abdominal pain (63%), nausea/emesis (69%), and hypotension (63%) with median duration of symptoms prior to presentation of 4.5 (IQR 3, 6) days.

Laboratory test results on admission are presented in Table 2 Imaging and echocardiogram findings are presented in Table 3 . Cardiomegaly was present in 10 (30%) of the patients. Focal or bilateral pulmonary opacities were noted in 11 (33%) patients.

To the best of our knowledge, none of the patients had typical lung disease as described in adults with COVID-19 pneumonia although none of these patients had computed tomography of the chest performed, limiting this evaluation. Echocardiograms were performed in 32 (97%) patients of which 21 (65.6%) had depressed left ventricle (LV) ejection fraction (<50%). Of the patients with depressed LV EF, 4 (12%) had an EF < 30%, and 17 (53%) had an EF between 30-50%. Twenty-four (72%) patients had a second echocardiogram performed; 20/21 (95%) of those with depressed function had recovery of ventricular function with normal EF. Details of patients with depressed systolic function are described in Table 4 .

Medical therapies used are presented in Table 5 . Eighteen (54%) patients received intravenous immunoglobulin (IVIG); 17 (51%) received corticosteroids; 12 (36%) received tocilizumab; 7 9 (21%) received remdesivir under a compassionate-use; 4 (12%) received Anakinra, and 1 (3%) received convalescent plasma therapy. Vasoactive medications were used in 17 (51%) patients, with norepinephrine being the most commonly used agent in 10 (30%), followed by dopamine in 9 (27%) patients. Median duration of vasopressor use was 72 (IQR 48, 110) hours.

Anticoagulation was used in all patients with prophylactic dosing with enoxaparin in 5 (15%), therapeutic dose enoxaparin in 27 (82%), and therapeutic dose unfractionated heparin in 1 (3%). Empiric antibiotic coverage for less than 48 hours was given in 14 (42%) patients, and antibiotics for more than 48 hours was used in 15 (45%).

Five (15%) patients required invasive mechanical ventilation. Two (6%) patients required mechanical circulatory support, one each by extracorporeal membrane oxygenation (ECMO) and an intra-aortic balloon pump (IABP). A 5-year-old with severely depressed LV function and cardiogenic shock was cannulated for venoarterial ECMO within 24 hours of presentation but developed an ischemic brain infarction with subarachnoid hemorrhage on day 6 of ECMO. Lifesustaining therapies were withdrawn following neurological examination consistent with brain death. Support using an IABP was used for a 20-year-old male who presented with 3 days of fever, nausea, vomiting, diarrhea, and abdominal pain and was found to have severely depressed LV function. He required inotropic support with epinephrine and dobutamine infusions as well as intubation and mechanical ventilation. Due to rising serum lactate and troponin levels, he underwent diagnostic cardiac catheterization that excluded coronary artery stenosis or anatomic abnormality. An IABP was inserted with which he was supported for 24 hours. He was treated with methylprednisolone and convalescent plasma. He was weaned off invasive mechanical ventilation by day 3 of hospitalization and was discharged home on day 12.

Thirty-two patients were discharged home with a median duration of PICU stay of 4.7 (IQR 4, 8) days and hospital stay of 7.8 (IQR 6, 10.1) days. One (3%) patient died after withdrawal of care secondary to hemorrhagic stroke while on ECMO support as mentioned previously.

The clinical profile of COVID-19 MIS-C in our cohort of 33 children was heterogeneous in severity of illness, ranging from clinically stable patients with normal or mildly depressed myocardial function to decompensated circulatory shock requiring invasive mechanical ventilation and mechanical circulatory support.

Possible mechanisms of myocardial involvement are speculative and include direct viral invasion of myocytes, and systemic inflammatory response triggering myocyte injury, which can be compounded by myocardial ischemia secondary to hypotension. (10) In the absence of myocardial biopsy, it is difficult to discern the exact mechanism of myocardial involvement, but given elevation of inflammatory markers, absence of strong data on coronaviruses being cardiotropic (11), occurrence after appearance of CoV antibodies in most patients, and the fact that not all critically ill children with shock developed myocardial dysfunction, it is plausible that the myocardial injury and circulatory shock in COVID-19 is secondary to inflammatory mediators. Based on the positive antibody status and the elevated cytokines, especially IL-6, seen in our cohort, we hypothesize that this novel COVID-19 MIS-C is predominantly an antibody-mediated of other immune cell-mediated cytokine storm, with some contribution from direct myocardial injury. These findings suggest a potential role for both antiviral and immunomodulatory therapies in the treatment of MIS-C. In our cohort, remdesivir, a nucleoside analog that blocks virus replication, was used for patients with active SARS-CoV-2 infection, as evidenced by positive RT-PCR results. (12) However, for the vast majority of patients who have positive antibodies and cytokine storm, as evidenced by elevated inflammatory markers and IL-6 levels, immunomodulatory therapy has been the mainstay of treatment. IVIG or corticosteroids or both were given to most patients for anti-inflammatory and antibodymediating effects, and tocilizumab, an IL-6 receptor inhibitor which appears to mediate a significant portion of this cytokine storm and resulting myocardial injury, was used for children with high IL-6 levels. (13, 14) The reasons for an exaggerated inflammatory response leading to MIS-C following SARS-CoV-2 infection are unclear, although cytokine-mediated storm has been described with other viral infections, though to a lesser degree. Although initially thought to be SARS-CoV-2-associated Kawasaki disease (5), emerging data have shown MIS-C to be a separate entity with age as a distinguishing feature. In contrast to the infantile age distribution of Kawasaki disease, MIS-C is predominantly a disease of older children and adolescents, supported by the median age in our cohort of 10 years, which is consistent with other reports of MIS-C. (4, 6) Critical illness with COVID-19 in children is infrequent but reported with younger age and comorbidities being risk factors for severe disease. (1, 2) In contrast to the European studies (4, 6), our cohort had lower morbidity with 51% requiring vasopressor support, 15% requiring invasive mechanical ventilation, and only 6% requiring mechanical circulatory support. The median LVEF in our cohort was 44%, which is higher than that reported by Belhadjer et al in a cohort of 35 children in which almost one-third had severely depressed LV systolic function (LVEF <30%). (6) The use of inotropic support (80%), mechanical ventilatory (62%) and circulatory support (28%), therapy with IVIG (71%), and corticosteroids (34%) were all higher in their cohort compared with ours. Expectedly, recovery of LV function was higher in our cohort with 20/21 (95%) patients with depressed LV function having recovered LV function at hospital discharge compared with 71% in the report of Although isolated reports have described COVID-19 associated myocarditis in adults (15) , MIS-C appears to be a separate entity as shock and hemodynamic compromise in MIS-C can occur in the absence of laboratory evidence of myocardial inflammation, and with preserved cardiac function and rapid reversibility. The most common agent used for inotropic support was norepinephrine, consistent with management of inflammatory mediator-induced vasoplegic shock. Median vasopressor duration of 72 hours and median PICU stay of 4.6 days provide insight into the clinical courses of these patients, with improvement in the majority of patients by day 4-5 and discharge from hospital by day 7. The duration of vasopressor support and PICU stay were similar between patients, suggesting that a majority of patients required close hemodynamic monitoring in PICU and that therapies such as respiratory support are required secondary to hemodynamic derangement. Based on PICU and hospital lengths of stay, it appears that inflammatory markers and myocardial function improved by days hospital 4-7.

Further larger multicenter studies are needed to further elucidate the spectrum of disease, risk factors for more severe illness, and response to supportive and medical therapies including IVIG, corticosteroids, biologic modifying agents, and anticoagulation strategies. Long-term follow-up will be required to determine any sequelae of MIS-C on myocardial function. 

Epidemiology of COVID-19 Among Children in China

Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center

Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region

Hyperinflammatory shock in children during COVID-19 pandemic

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department

The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease

Acute Myocarditis and Pericarditis in Children

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Intravenous immunoglobulin in neurology--mode of action and clinical efficacy

Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19)

Reference range: BNP-0-100 pg/mL; *Pro-BNP 0-450 pg/mL (highest reported value: > 15000)

01 ng/mL H: Hispanic; B: black; W: white; A: Asian; Adm: admission; LVEF: left ventricular ejection fraction

Prom: prominent; IVIG: intravenous immune globulin; Toci: Tocilizumab; Conv plas: convalescent plasma therapy

ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; REM: Remdesivir; MP: methylprednisolone; ANK: Anakinra Diuretics